Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.

ABSTRACT:

Background

α1-Adrenergic receptor antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit tumor growth. This study evaluated the risk of prostate cancer death in men using α1-adrenergic receptor antagonists.

Methods

A population-based cohort study in Stockholm, Sweden (January 1, 2007, to December 31, 2019) included 451 779 men with a prostate-specific antigen test result. Study entry was 1 year after the first prostate-specific antigen test. Men were considered exposed at their second filled prescription. The primary outcome was prostate cancer mortality. Secondary outcomes were all-cause mortality and prostate cancer incidence. Cox proportional hazards regression models were used to calculate

SUBMITTER: Bjornebo L 

PROVIDER: S-EPMC11378311 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature